Janssen Biotech Inc. Release: New Data Demonstrate STELARA® (Ustekinumab) is Effective and Improves Quality of Life in Patients With Moderate to Severe Plaque Psoriasis
HIGH WYCOMBE, UK--(BUSINESS WIRE)--A series of data presentations released at the 21st European Academy of Dermatology and Venereology (EADV) congress, in Prague, Czech Republic, demonstrate that STELARA® (ustekinumab) is effective, generally well-tolerated and improves quality of life in patients with moderate-to-severe plaque psoriasis.